p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours

Area of Science:

• Oncology
• Molecular Pathology
• Tumor Biology

Background:

• Inflammatory myofibroblastic tumors (IMT) have poorly understood pathogenic mechanisms and predictive indicators of biological behavior.
• The role of molecular abnormalities, specifically p53 and MDM2, in IMT pathogenesis and aggressive phenotype requires further investigation.

Purpose of the Study:

• To investigate molecular abnormalities of p53 and MDM2 in IMT.
• To assess the role of these abnormalities in IMT pathogenesis.
• To determine if p53 and MDM2 alterations contribute to a clinicopathological aggressive phenotype in IMT.

Main Methods:

• Immunohistochemical analysis of calponin, h-caldesmon, ALK, p53, and MDM2 expression in 15 IMT cases.
• p53 gene mutation analysis using polymerase chain reaction single-strand conformation polymorphism and direct sequencing.
• MDM2 gene amplification analysis.
• Correlation of molecular findings with clinicopathological features, including cellular atypia and recurrence.

Main Results:

• Cellular atypia was observed in 33.3% of cases; local recurrences in 14.3% of informative cases.
• Myofibroblastic differentiation suggested by calponin expression (64%) but not h-caldesmon.
• ALK expression observed in 53.3% of cases, particularly in patients under 40.
• p53 protein nuclear expression in 6.7% and missense mutations in 13.3% of cases.
• MDM2 nuclear expression in 26.7% and gene amplification in 2 of those cases.

Conclusions:

• Inflammatory myofibroblastic tumors exhibit diverse cellular atypia and biological behaviors.
• p53 and MDM2 expression is present in IMT, but alterations in the p53 pathway do not appear to be a major factor in IMT pathogenesis.
• Further research may be needed to fully elucidate the molecular drivers of IMT aggressiveness.